Revolution Medicines, Inc.
RVMD- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001628171
In the last 90 days, Revolution Medicines, Inc. insiders filed 0 open-market purchases and 21 sales; 698 institutions reported holding it in 13F filings for Q2 2026, worth $40.1B in total; Duquesne Family Office is the only superinvestor holding it.
Other share classesRVMDW
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:19 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 25, 2026 | Feb 26, 2025 | Jan 9, 2024 | Jan 10, 2023 | Jan 11, 2022 |
| Revenue | $0 | $0 | $11.6M | $35.4M | $29.4M |
| Operating expenses | $1.18B | $689.5M | $498.8M | $293.7M | $217.4M |
| Research and development | $987.3M | $592.2M | $423.1M | $253.1M | $186.9M |
| Selling, general and administrative | $195.0M | $97.3M | $75.6M | $40.6M | $30.4M |
| Operating income | -$1.18B | -$689.5M | -$487.2M | -$258.3M | -$188.0M |
| Interest expense | – | – | – | $0 | $12.0K |
| Income tax | $0 | -$753.0K | -$3.52M | -$420.0K | $0 |
| Net income | -$1.13B | -$600.1M | -$436.4M | -$248.7M | -$187.1M |
| EPS, basic | $-5.95 | $-3.58 | $-3.86 | $-3.08 | – |
| EPS, diluted | $-5.95 | $-3.58 | $-3.86 | $-3.08 | – |
| Weighted shares, basic | 190.1M | 167.7M | 113.1M | 80.6M | – |
| Weighted shares, diluted | 190.1M | 167.7M | 113.1M | 80.6M | – |
| Margins and growth | |||||
| Operating margin | – | – | -4207.1% | -730.0% | -639.7% |
| Net margin | – | – | -3768.3% | -703.0% | -636.6% |
| Revenue growth, year over year | – | −100.0% | −67.3% | +20.4% | −31.6% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 25, 2026 | Feb 26, 2025 | Jan 9, 2024 | Jan 10, 2023 | Jan 11, 2022 |
| Cash and equivalents | $383.7M | $543.1M | $696.1M | $161.4M | $108.5M |
| Short-term investments | $1.64B | $1.75B | $1.16B | $483.5M | $468.6M |
| Total current assets | $2.08B | $2.33B | $1.88B | $660.2M | $589.8M |
| Property, plant and equipment | $33.2M | $24.3M | $22.9M | $18.7M | $11.5M |
| Goodwill | $14.6M | $14.6M | $14.6M | $14.6M | $14.6M |
| Intangible assets | $55.8M | $56.7M | $57.7M | $58.8M | $59.9M |
| Total assets | $2.35B | $2.56B | $2.06B | $811.9M | $738.0M |
| Accounts payable | $64.6M | $54.4M | $61.8M | $21.3M | $14.1M |
| Total current liabilities | $290.4M | $163.9M | $143.9M | $62.0M | $60.4M |
| Total liabilities | $723.2M | $293.1M | $235.5M | $126.7M | $135.4M |
| Shareholders' equity | $1.63B | $2.27B | $1.83B | $685.2M | $602.6M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 25, 2026 | Feb 26, 2025 | Jan 9, 2024 | Jan 10, 2023 | Jan 11, 2022 |
| Operating cash flow | -$897.7M | -$557.4M | -$350.6M | -$224.4M | -$147.2M |
| Capital expenditures | $16.0M | $10.3M | $7.73M | $10.8M | $6.53M |
| Free cash flow | -$913.7M | -$567.7M | -$358.3M | -$235.2M | -$153.7M |
| Depreciation and amortization | $7.78M | $6.56M | $5.00M | $3.97M | $3.08M |
| Stock-based compensation | $118.4M | $79.2M | $61.8M | $31.2M | $20.7M |
| Investing cash flow | $118.1M | -$554.4M | -$342.6M | -$24.1M | -$142.1M |
| Financing cash flow | $621.5M | $959.4M | $1.23B | $301.4M | $294.2M |
| Net change in cash | -$158.2M | -$152.4M | $536.0M | $52.9M | $4.88M |
| Ratio | |||||
| Stock-based compensation, % of revenue | – | – | 533.4% | 88.2% | 70.5% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 30, 2026 | 216.3M | +11.9% | SEC |
| Jul 31, 2026 | 214.3M | +14.7% | SEC |
| May 1, 2026 | 212.6M | +14.1% | SEC |
| Feb 20, 2026 | 198.2M | +6.6% | SEC |
| Oct 31, 2025 | 193.3M | +14.9% | SEC |
| Aug 1, 2025 | 186.9M | +11.9% | SEC |
| May 2, 2025 | 186.3M | +12.9% | SEC |
| Feb 21, 2025 | 185.9M | +12.9% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.